Vox Markets Logo

PayPoint considers buyback after strong full year

09:45, 22nd April 2024
Vox News
Company News
TwitterFacebookLinkedIn

PayPoint (PAY) Follow | PAY said on Monday that it was mulling a potential share buyback after a strong full-year performance.
In a post-close update for the year to the end of March 2024, the company said it expects underlying earnings before interest, tax, depreciation and amortisation to be in excess of £80m.

Year-end net debt is expected to be below £70m and underlying pre-tax profit in line with expectations, as outlined in the third-quarter update in January.

"The strength of this performance, underpinned by sustained strong cash flow and our confidence in the delivery of continued growth and achieving our financial targets, has enabled the board to now have under active consideration a share buyback programme to further enhance shareholder returns," it said.

At 1010 BST, the shares were up 7.2% at 521.02p.

Stock Chart | PAY
TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
  • London close: Stocks rise as US payrolls come in weaker

    3 hours ago

    London markets closed positively on Friday, as investors digested slower-than-expected payrolls growth in the US, while Anglo American jumped amid anticipation of a potential bidding war for the mining giant.

  • FTSE 250 movers: Trainline rolling; Georgia banks out of favour

    3 hours ago

    FTSE 250 (MCX) 20,198.09 0.73%

  • FTSE 100 movers: Anglo rallies on Reuters report; IHG slumps

    3 hours ago

    London's FTSE 100 was up 0.5% at 8,209.34 in afternoon trade on Friday.

  • Berenberg raises target price on Standard Chartered

    5 hours ago

    Analysts at Berenberg raised their target price on multinational bank Standard Chartered from 1,050.0p to 1,100.0p on Friday after the group's Q1 earnings "validated" management's suggestion that the bank had experienced "an encouraging start" to the year.

  • Citi sees significant upside at Team17

    5 hours ago

    Citi has reiterated its 'buy' rating for British video-game developer Team17, saying it sees significant upside to its valuation as operations stabilise.

  • Jefferies downgrades AJ Bell after share price rally

    5 hours ago

    Jefferies downgraded its stance on AJ Bell on Friday to 'hold' from 'buy' after a circa 30% rally in the shares this year.

  • Triple Point to sell part of portfolio after shareholder consultation

    5 hours ago

    Triple Point Social Housing announced plans to sell part of its portfolio on Friday, following shareholder consultations.

  • Adriatic Metals announces resignation of CFO

    5 hours ago

    Adriatic Metals, the FTSE 250 precious and base metals miner, has announced that its chief financial officer is stepping down after just two years on the job.

  • CMA set for deeper probe of Pennon's SES acquisition

    5 hours ago

    Pennon Group worked to assure the market that its acquisition of Sutton and East Surrey Water (SES Water) would avoid a deeper competition probe on Friday, telling shareholders that it planned to offer "appropriate undertakings" to regulators.

  • Angle strikes supplier deal with AstraZeneca

    5 hours ago

    Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Watchlist